



Ref: FOIA Reference 2020/21-551

Date: 14th April 2021

Email foi@uhn.nhs.uk

Dear

I am writing in response to your email dated 1st March 2021 requesting information under the Freedom of Information Act (2000) regarding drug usage

The University Hospitals of North Midlands Trust is committed to the Freedom of Information Act 2000.

However, the NHS is facing unprecedented challenges relating to the coronavirus (COVID-19) pandemic at the current time. Understandably, our resources have been diverted to support our front-line colleagues who are working tremendously hard to provide care for our patients, and to those in need of our services.

We strive to be transparent and to work with an open culture. But at this time, whilst care of our patients and the safety of our staff takes precedent, it is likely that responses to some requests for information will be delayed. We apologise for this position in advance, and will endeavour to provide you with as much information as we can, as soon as we are able.

The Information Commissioners Office has recognised the current situation in the NHS

On 2nd March 2021 we contacted you via email as we required the following information:
Please provide the specific SNOMED coding for AE information as we do not code with ICD10 coding to AE information.

On 22nd March 2021 you replied via email with:

“Apologies for the delayed response. The SNOMED Concept IDs for HAE that we are interested in are 82966003 and 41291007”

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 Could you please provide answers to the following three questions?

In the past 6 months [latest 6 months available] how many patients have received the following treatments [for any disease]:

- **Berinert (Human C1-esterase inhibitor)**
- **Cinryze (Human C1-esterase inhibitor)**
- **Takhzyro (Lanadelumab)**
- **Ruconest (Recombinant human C1-esterase inhibitor)**

- **Firazyr (Icatibant injection)**

A1 See below:

- Berinert (Human C1-esterase inhibitor) = 10
- Cinryze (Human C1-esterase inhibitor) = 8
- Takhzyro (Lanadelumab) = 6
- Ruconest (Recombinant human C1-esterase inhibitor) = 0
- Firazyr (Icatibant injection) = 11

Q2 In the past 6 months [latest 6 months available] how many patients have received the following immunoglobulin treatments [for any disease]:

- **Cuvitru**
- **Gammanorm**
- **Gamunex**
- **Hizentra**
- **Hyqvia**
- **Kiovig**
- **Octagam**
- **Privigen**
- **Subgam**

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below

- Cuvitru = <5
- Gammanorm = 9
- Gamunex = <5
- Hizentra = 19
- Hyqvia = 0
- Kiovig = 0
- Octagam = <5
- Privigen = 67
- Subgam = 0

Q3 In the past 6 months, how many patients attended A&E for Hereditary Angioedema (ICD10 code: D84.1) or Angioedema (ICD10 code: T78.3)? Of these patients, how many were treated with the following products:

- **Berinert (Human C1-esterase inhibitor)**
- **Cinryze (Human C1-esterase inhibitor)**
- **Ruconest (Recombinant human C1-esterase inhibitor)**
- **Firazyr (Icatibant injection)**

A3 See below:

- Berinert (Human C1-esterase inhibitor) = 0
- Cinryze (Human C1-esterase inhibitor) = 0
- Ruconest (Recombinant human C1-esterase inhibitor) = 0
- Firazyr (Icatibant injection) = 0

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



University Hospitals
of North Midlands
NHS Trust

Jean Lehnert
Data, Security & Protection Manager

